Emerging evidence suggests that immune checkpoint inhibitors (ICIs) and Delta-like ligand 3 (DLL3)-targeted therapies may offer promising alternatives for a subset of EP-NEC patients. The gene discussed is DLL3; the disease is neuroendocrine carcinoma.